Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 6,459,973 Shares of Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) major shareholder Group Walters purchased 6,459,973 shares of the company’s stock in a transaction on Wednesday, December 31st. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the purchase, the insider directly owned 13,509,973 shares in the company, valued at approximately $16,211,967.60. This trade represents a 91.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $2.84 on Friday. The stock has a market capitalization of $205.19 million, a P/E ratio of -1.37 and a beta of 1.75. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $3.06. The business has a 50-day moving average of $1.43 and a 200-day moving average of $1.48.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.12. Equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Institutional Trading of Zentalis Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ZNTL. Acadian Asset Management LLC increased its position in Zentalis Pharmaceuticals by 150.6% during the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock worth $4,244,000 after buying an additional 1,606,802 shares during the last quarter. Tybourne Capital Management HK Ltd. boosted its stake in shares of Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after acquiring an additional 516,666 shares during the period. Savant Capital LLC bought a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at $59,000. Public Employees Retirement System of Ohio lifted its holdings in Zentalis Pharmaceuticals by 351.7% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 36,700 shares of the company’s stock valued at $43,000 after purchasing an additional 28,576 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Zentalis Pharmaceuticals by 50.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 348,965 shares of the company’s stock valued at $555,000 after purchasing an additional 116,907 shares during the last quarter.

Analyst Ratings Changes

ZNTL has been the topic of a number of research reports. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th. Morgan Stanley cut their price target on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 12th. Leerink Partners restated a “market perform” rating and set a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.53.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.